Advertisement
Allergan
Subscribe to Allergan

The Lead

Family Gets $6.75M in Botox Treatment Case

November 21, 2014 8:04 am | by DAVE GRAM, Associated Press | News | Comments

A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.        

Actavis to Spend $66B on Allergan

November 17, 2014 10:24 am | by TOM MURPHY, AP Business Writer | News | Comments

Actavis will pay $66 billion to buy fellow drugmaker Allergan in a deal that could finally stop...

Allergan Soars on Deal Reports

November 17, 2014 8:11 am | by The Associated Press | News | Comments

Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the...

Allergan Amends Company’s Bylaws Prior to Stockholder's Meeting

November 12, 2014 8:12 am | News | Comments

Allergan today announced that its Board of Directors has approved amendments to the company’s...

View Sample

FREE Email Newsletter

Allergan Deal Inches Forward with Court's Decision

November 4, 2014 6:01 pm | by The Associated Press | News | Comments

In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan's upcoming shareholder meeting.  Allergan said in a statement Tuesday that it will file an emergency appeal.    

Valeant: We'll Bump Allergan Offer to $200 a Share

October 27, 2014 7:33 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International says it will raise its offer for Botox maker Allergan to $200 or more per share. Valeant made the statement in a letter to Allergan's board released publicly seeking to urge Allergan to talk about an acquisition.

Valeant Considering Higher Bid for Allergan after Reporting Strong Q3 Results

October 20, 2014 1:26 pm | by Ross Marowits, The Canadian Press | News | Comments

Valeant Pharmaceuticals said that its strong third-quarter results and a higher growth forecast give it ammunition to win over reluctant takeover target Botox maker Allergan with an increased bid at the appropriate time.     

Advertisement

Allergan Boosts Outlook

October 9, 2014 1:54 pm | News | Comments

Allergan, which has been fending off buyout offers from Valeant Pharmaceuticals, boosted its earnings outlook for the year and current quarter.                  

Pressure Mounting on Allergan as Proxy Firm ISS Criticizes Board Approach

October 2, 2014 3:52 pm | by Ross Marowits, The Canadian Press | News | Comments

Proxy advisory firm Institutional Shareholder Services has joined several large Allergan shareholders calling for a vote after reports surfaced that it is in talks to buy Salix Pharmaceuticals. The US$10 billion all-cash deal could make it too expensive for Valeant to purchase the company.

FDA Approves Revised Indication for Allergan's OZURDEX®

September 29, 2014 10:06 am | News | Comments

Allergan announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema (DME).  

Pershing Capital Threatens to Sue Allergan if it Acquires Salix Without Vote

September 23, 2014 2:40 pm | by Ross Marowits, The Canadian Press | News | Comments

Allergan's largest shareholder, Pershing Square Capital, has threatened to sue the Botox maker if it attempts to buy Salix Pharmaceuticals without holding a shareholder vote. The investment fund headed by Bill Ackman has teamed up with Valeant Pharmaceuticals to make a $50-billion hostile takeover bid for Allergan.

Allergan Agrees to Move Forward with Meeting

September 16, 2014 6:44 am | by The Associated Press | News | Comments

Allergan and Pershing Square are agreeing on at least one step toward settling a fight over the makeup of the Botox-maker's board. Allergan will hold special shareholders meeting, as Pershing Square and its partner, Valeant Pharmaceuticals, continue their push for control of the drugmaker.

Advertisement

Allergan to Request Court Block Valeant and Pershing Square from Voting Shares Acquired in Violation of Insider Trading Laws

August 27, 2014 8:27 am | News | Comments

Allergan has asked the United States District Court for the Central District of California to set an expedited schedule for discovery and a motion for a preliminary injunction against Valeant Pharmaceuticals, Pershing Square Capital Management, L.P., and its principal, William A. Ackman, for violations of the federal securities laws.

Allergan Reviews Meeting Requests in Takeover Bid

August 23, 2014 2:27 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most of its board, a change fellow drugmaker Valeant Pharmaceuticals International Inc. is seeking as part of the hostile takeover attempt it's been waging since April. Allergan has repeatedly...

Allergan Acquires LiRIS® Program from TARIS Biomedical®

August 14, 2014 8:43 am | News | Comments

Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical's® lead program, LiRIS®, which is currently in Phase 2 trials for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).      

Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino

August 12, 2014 8:39 am | News | Comments

Valeant Pharmaceuticals International  announced that the company has received a request for additional information from the Federal Trade Commission in connection with Valeant's proposed acquisition of Allergan, Inc.      

Allergan Sues Valeant, Claims Fraud in Buy Attempt

August 1, 2014 3:34 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Allergan Inc.'s lawsuit, filed Friday in U.S. District Court in Santa Ana, California, names as plaintiffs drugmaker Valeant Pharmaceuticals International Inc., New York investment and hedge fund firm Pershing Square Capital Management LP and its principal, William Ackerman.

Advertisement

Allergan's OZURDEX® Receives European Positive Opinion for the Treatment of Diabetic Macular Edema

July 25, 2014 8:03 am | News | Comments

Allergan announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has recommended extending the Marketing Authorization for OZURDEX ® (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with vision loss due to diabetic macular edema.

Allergan Reports Second Quarter 2014 Operating Results; Announces Layoffs

July 21, 2014 8:45 am | News | Comments

Allergan, Inc. announced operating results for the quarter ended June 30, 2014 and announced a restructuring that will eliminate 1500 jobs.                   

Valeant Takes Allergan Complaints to Regulators

July 21, 2014 8:23 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International Inc. is complaining to regulators that Botox maker and acquisition target Allergan has been making false statements about its business.             

Pershing Files Documents for Special Meeting Aimed at Ousting Allergan Directors

July 7, 2014 3:05 pm | by The Canadian Press | News | Comments

Pershing Square Capital Management has formally asked Allergan shareholders to support its bid for a special meeting to remove six directors and allow Valeant to proceed with its hostile takeover bid.        

Pershing Square Settles Lawsuit with Allergan

June 27, 2014 3:28 pm | by The Associated Press | News | Comments

Pershing Square, the investment firm run by activist investor Bill Ackman, said Friday it settled a lawsuit with Allergan, the maker of Botox, related to Allergan's poison pill plan and Pershing's $53 billion offer for the company.   

Allergan Board of Directors Rejects Unsolicited Exchange Offer from Valeant

June 23, 2014 8:23 am | News | Comments

Allergan, announced that its Board of Directors, after consultation with its independent financial and legal advisors, unanimously determined that Valeant Pharmaceuticals International, Inc.’s unsolicited exchange offer to acquire all outstanding common shares of Allergan is grossly inadequate.

Ackman Seeks Allergan 'Poison Pill' End Run

June 13, 2014 8:14 am | News | Comments

Bill Ackman's Pershing Square Capital Management, seeking legal cover in its $53 billion takeover bid for Allergan, filed a lawsuit to confirm that its push for a special meeting of shareholders won't trigger a defensive "poison pill" plan from the Botox maker.

Valeant Plans Hostile Bid for Allergan

June 10, 2014 5:31 pm | by Tom Murphy - AP Business Writer - Associated Press | News | Comments

Valeant Pharmaceuticals aims to take its bid for Allergan to the Botox maker's shareholders after Allegan's board unanimously rejected its latest offer of about $53 billion. Valeant said Tuesday that it looked forward to giving shareholders the opportunity "to speak for themselves" after Allergan Chairman and CEO David Pyott said that the offer wasn't worth discussing in a letter to his Valeant counterpart, Michael Pearson.

Allergan Board Unanimously Rejects Revised Unsolicited Proposal from Valeant

June 10, 2014 8:33 am | News | Comments

Allergan announced that its Board of Directors has unanimously determined that the revised unsolicited proposal from Valeant Pharmaceuticals substantially undervalues the company, creates significant risks and uncertainties for the stockholders of Allergan, and is not in the best interests of the company and its stockholders.

Allergan Tops 2014 Newsweek Green Rankings

June 5, 2014 8:13 am | News | Comments

The Newsweek Green Rankings evaluate the world's largest publicly traded companies using eight metrics that collectively provide a transparent measurement of overall corporate environmental performance. Companies were scored on each metric against their industry peers using a 0-100% scale.

Proxy Fight Looms in Allergan-Valeant Dispute

June 2, 2014 3:42 pm | News | Comments

Activist investor Bill Ackman said Monday that he will move to replace most of Allergan's board of directors as part of a continuing battle for control of the company.              

Valeant Sweetens Offer for Allergan Again

May 30, 2014 4:01 pm | by ALEX VEIGA, AP Business Writer | News | Comments

Valeant Pharmaceuticals is sweetening its offer to buy Botox maker Allergan for the second time this week. The Canadian drugmaker said Friday it is now offering $72 and a portion of its stock for each Allergan share.      

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading